Kura Oncology (KURA) Stock Forecast & Price Target

Kura Oncology is supported by a differentiated menin-inhibitor franchise that is showing strong commercial traction, with KOMZIFTI generating $9.1M of revenue in 2Q26, 115 new patient starts, and over 250 total prescriptions, while capturing a majority of new starts in r/r NPM1-mutant AML. Its core investment case is reinforced by compelling clinical data from KOMET-007, including 96% CRc in NPM1-mutant AML, 94% 12-month OS, durable responses not yet reached, and a clean safety profile with no ziftomenib-related QTc events, supporting broad combination use. With $519M to $580.8M in cash, plus $180M in expected collaboration payments, and multiple 2026 and 2H26 catalysts across AML, solid tumors, and FLT3 combinations, the company appears well financed to advance a potentially expanded ~$7B front-line opportunity.

Kura Oncology is facing a weak fundamental case because ziftomenib may prove less efficacious in AML than expected, while its safety profile appears insufficiently differentiated versus competitors, reducing confidence in its clinical upside and leaving the program with only a 10% probability of success in the bear case. Its broader pipeline also carries substantial execution risk, since tipifarnib depends on difficult biomarker identification and patent-extension efforts, while approval from the FDA and foreign regulators remains uncertain and any delay could hurt commercialization. Although the company is currently well-funded with cash, cash equivalents, and short-term investments, it may still need additional equity financing or non-dilutive capital, and its focus on smaller niches like NUP98r limits the commercial opportunity versus larger AML populations.